The right biomarker, read correctly, can surface disease long before standard labs catch it. Dr. Mollie James sorts the biomarker landscape into clear categories, compares routine testing with emerging tools like continuous monitoring and mitochondrial function assays, and shows how to read complex multi-parameter patterns rather than isolated values. She ties it back to real decisions, with a look ahead at how multi-omics and AI are reshaping precision medicine.

Learning objectives

By the end of this session, participants will be able to:

1. Define the term biomarker and differentiate between diagnostic, predictive, prognostic, and response biomarkers, with clinical examples relevant to cardiometabolic, oncologic, and neurocognitive conditions.
2. Compare traditional laboratory testing with emerging biomarker technologies, including continuous monitoring systems, microvascular assessment, and mitochondrial function testing, in terms of clinical utility and limitations.
3. Interpret multi-parameter biomarker data (advanced lipids, inflammatory markers, hormonal patterns) to identify early disease states and physiologic dysfunction not captured by standard testing.
4. Integrate advanced biomarker data into patient-specific diagnostic and treatment strategies, including risk stratification, therapeutic targeting, and monitoring of clinical response.
5. Assess the role of multi-omics, artificial intelligence, and systems-based diagnostics in shaping the future of precision medicine and personalized patient care.